Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, Lintermans B, Goossens S, Lammens T, Van Roy N, Touzart A, Jenni S, Tsai YC, Lovisa F, Mussolin L, Serafin V, Van Nieuwerburgh F, Deforce D, Uyttebroeck A, Tousseyn T, Burkhardt B, Klapper W, De Moerloose B, Benoit Y, Macintyre E, Bourquin JP, Basso G, Accordi B, Bornhauser B, Meijerink J, Vandenberghe P, Van Vlierberghe P.

Haematologica. 2019 Jan;104(1):e17-e20. doi: 10.3324/haematol.2018.199257. Epub 2018 Aug 3. No abstract available.

2.

Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia.

Milani G, Matthijssens F, Van Loocke W, Durinck K, Roels J, Peirs S, Thénoz M, Pieters T, Reunes L, Lintermans B, Vandamme N, Lammens T, Van Roy N, Van Nieuwerburgh F, Deforce D, Schwab C, Raimondi S, Dalla Pozza L, Carroll AJ 3rd, De Moerloose B, Benoit Y, Goossens S, Berx G, Harrison CJ, Basso G, Cavé H, Sutton R, Asnafi V, Meijerink J, Mullighan C, Loh M, Van Vlierberghe P.

Br J Haematol. 2018 Jun 25. doi: 10.1111/bjh.15425. [Epub ahead of print] No abstract available.

PMID:
29938777
3.

Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.

Peirs S, Frismantas V, Matthijssens F, Van Loocke W, Pieters T, Vandamme N, Lintermans B, Dobay MP, Berx G, Poppe B, Goossens S, Bornhauser BC, Bourquin JP, Van Vlierberghe P.

Leukemia. 2017 Oct;31(10):2037-2047. doi: 10.1038/leu.2017.10. Epub 2017 Jan 11.

4.

Characterization of the interaction between the dopamine D4 receptor, KLHL12 and β-arrestins.

Skieterska K, Shen A, Clarisse D, Rondou P, Borroto-Escuela DO, Lintermans B, Fuxe K, Xiang YK, Van Craenenbroeck K.

Cell Signal. 2016 Aug;28(8):1001-14. doi: 10.1016/j.cellsig.2016.05.003. Epub 2016 May 5.

PMID:
27155323
5.

KLHL12 Promotes Non-Lysine Ubiquitination of the Dopamine Receptors D4.2 and D4.4, but Not of the ADHD-Associated D4.7 Variant.

Skieterska K, Rondou P, Lintermans B, Van Craenenbroeck K.

PLoS One. 2015 Dec 30;10(12):e0145654. doi: 10.1371/journal.pone.0145654. eCollection 2015.

6.

Detection of G protein-coupled receptor (GPCR) dimerization by coimmunoprecipitation.

Skieterska K, Duchou J, Lintermans B, Van Craenenbroeck K.

Methods Cell Biol. 2013;117:323-40. doi: 10.1016/B978-0-12-408143-7.00017-7.

PMID:
24143985
7.

Biochemical and pharmacological study of N-linked glycosylation of the human serotonin 5-HT₇a receptor.

Gellynck E, Andressen KW, Lintermans B, Haegeman G, Levy FO, Vanhoenacker P, Van Craenenbroeck K.

FEBS J. 2012 Jun;279(11):1994-2003. doi: 10.1111/j.1742-4658.2012.08581.x. Epub 2012 Apr 25.

8.

RhoBTB3 interacts with the 5-HT7a receptor and inhibits its proteasomal degradation.

Matthys A, Van Craenenbroeck K, Lintermans B, Haegeman G, Vanhoenacker P.

Cell Signal. 2012 May;24(5):1053-63. doi: 10.1016/j.cellsig.2011.12.027. Epub 2012 Jan 5.

PMID:
22245496
9.

Inducible production of recombinant human Flt3 ectodomain variants in mammalian cells and preliminary crystallographic analysis of Flt3 ligand-receptor complexes.

Verstraete K, Remmerie B, Elegheert J, Lintermans B, Haegeman G, Vanhoenacker P, Van Craenenbroeck K, Savvides SN.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Mar 1;67(Pt 3):325-31. doi: 10.1107/S1744309111003319. Epub 2011 Feb 23.

10.

Dopamine D4 receptor oligomerization--contribution to receptor biogenesis.

Van Craenenbroeck K, Borroto-Escuela DO, Romero-Fernandez W, Skieterska K, Rondou P, Lintermans B, Vanhoenacker P, Fuxe K, Ciruela F, Haegeman G.

FEBS J. 2011 Apr;278(8):1333-44. doi: 10.1111/j.1742-4658.2011.08052.x. Epub 2011 Mar 10.

11.

KLHL12-mediated ubiquitination of the dopamine D4 receptor does not target the receptor for degradation.

Rondou P, Skieterska K, Packeu A, Lintermans B, Vanhoenacker P, Vauquelin G, Haegeman G, Van Craenenbroeck K.

Cell Signal. 2010 Jun;22(6):900-13. doi: 10.1016/j.cellsig.2010.01.014. Epub 2010 Jan 25.

PMID:
20100572
12.

Cooperation of NFkappaB and CREB to induce synergistic IL-6 expression in astrocytes.

Spooren A, Kooijman R, Lintermans B, Van Craenenbroeck K, Vermeulen L, Haegeman G, Gerlo S.

Cell Signal. 2010 May;22(5):871-81. doi: 10.1016/j.cellsig.2010.01.018. Epub 2010 Jan 25. Erratum in: Cell Signal. 2011 Aug;23(8):1413-4.

PMID:
20100571
13.

Resistance of the dopamine D4 receptor to agonist-induced internalization and degradation.

Spooren A, Rondou P, Debowska K, Lintermans B, Vermeulen L, Samyn B, Skieterska K, Debyser G, Devreese B, Vanhoenacker P, Wojda U, Haegeman G, Van Craenenbroeck K.

Cell Signal. 2010 Apr;22(4):600-9. doi: 10.1016/j.cellsig.2009.11.013. Epub 2009 Nov 20.

PMID:
19932171
14.

Cloning, genomic organization and functionality of 5-HT(7) receptor splice variants from mouse brain.

Gellynck E, Laenen K, Andressen KW, Lintermans B, De Martelaere K, Matthys A, Levy FO, Haegeman G, Vanhoenacker P, Van Craenenbroeck K.

Gene. 2008 Dec 15;426(1-2):23-31. doi: 10.1016/j.gene.2008.08.011. Epub 2008 Aug 27.

PMID:
18793707
15.

Influence of the antipsychotic drug pipamperone on the expression of the dopamine D4 receptor.

Van Craenenbroeck K, Gellynck E, Lintermans B, Leysen JE, Van Tol HH, Haegeman G, Vanhoenacker P.

Life Sci. 2006 Dec 3;80(1):74-81. Epub 2006 Aug 25.

PMID:
16978659
16.

Novel interaction between the human 5-HT7 receptor isoforms and PLAC-24/eIF3k.

De Martelaere K, Lintermans B, Haegeman G, Vanhoenacker P.

Cell Signal. 2007 Feb;19(2):278-88. Epub 2006 Aug 28.

PMID:
16935469
17.

[Needless delay in vulvar carcinoma].

Lintermans B.

Ned Tijdschr Geneeskd. 1991 Oct 5;135(40):1876-7. Dutch. No abstract available.

PMID:
1944644

Supplemental Content

Loading ...
Support Center